Abstract: Embodiments of the invention provide shaped masses (SM) comprising one or more drugs such as proteins or polypeptides and methods for forming and delivering such SM's. One embodiment provides a SM comprising a drug e.g., a protein or polypeptide having a biological activity in the body of a mammal. The SM is formed by compression of a precursor material (PM) comprising the drug wherein an amount of biologically active drug in the SM is a minimum level to that in the PM. Drugs which may be incorporated into the SM include insulin, incretins and immunoglobulins e.g., interleukin neutralizing antibodies or TNF-?-inhibiting antibodies. Embodiments of the invention are particularly useful for the oral delivery of drugs which would be degraded within the GI tract, wherein the SM containing the drug is formed as or incorporated into a tissue penetrating member which is inserted into the intestinal wall after oral ingestion.

Abstract: The invention is based on observing that LIF is capable of activating the self-renewal of tumor stem cells in cancer, in particular gliomas, which indicates that the inhibition of LIF, and generally of IL-6 type cytokines, can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation. The invention also relates to a method for the identification of compounds capable of blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of subjects suffering from said tumors.

Abstract: The present invention relates to a method for preparing anti-mammalian AMH antibodies comprising the steps of: (i) immunizing an animal with an AMH polypeptide or a polynucleotide encoding this AMH polypeptide, said AMH polypeptide comprising at least the 99 amino acids of sequence SEQ ID No. 1 or of a sequence having at least 75% identity with the sequence SEQ ID No. 1, and at most the 560 amino acids of sequence SEQ ID No. 2 or of a sequence having at least 75% identity with the sequence SEQ ID No. 2, (ii) preparing hybridomas from cells of a lymphoid organ of the animal having received the immunogen, (iii) selecting hybridomas secreting antibodies recognizing an AMH polypeptide comprising at least the 99 amino acids of sequence SEQ ID No. 1 or of a sequence having at least 75% identity with the sequence SEQ ID No. 1, and at most the 255 amino acids of sequence SEQ ID No. 8 or of a sequence having at least 75% identity with the sequence SEQ ID No.

Abstract: Effector-deficient anti-CD32a monoclonal antibodies are encompassed, as are method and uses for treating CD32a-mediated diseases and disorders, including, thrombocytopenia, allergy, hemostatic disorders, immune, inflammatory, and autoimmune disorders.

Abstract: Provided herein are methods of treating a subject, methods of predicting the response of a subject and selecting a subject suffering from a disease associated with myeloid cell dysfunction. In particular, provided herein are methods for treatment or diagnosis of a disease associated with myeloid cell dysfunction, such as Alzheimer's Disease (AD) and Herpes Simplex Virus-1 (HSV-1) infection, with an agent specifically binding to Paired Immunoglobulin-like Type 2 Receptor Alpha (PILRA), such as an antibody as well as pharmaceutical formulations comprising the same.

Abstract: The invention provides methods and compositions for treating Siglec-9 mediated cancer in a subject, where the cells of the cancer express sialylated Core-1-MUC1 glycoproteins that engage with Siglec-9 expressed on certain immune cells, for example, monocytes and macrophages of the subject. Prior to treatment, the cancerous cells may evade the immune system of the host by binding Siglec-9 expressed by the immune cells, whereupon binding activates a number of pro-tumorigenic, Siglec-9 mediated activities in or via the immune cells. However, when treated with an inhibitor of Siglec-9 activity, the Siglec-mediated activities can be mitigated and the host immune system can recognize and elicit an immune response against the cancer cells expressing the sialylated Core-1 MUC1 glycoproteins.

Abstract: The invention is among others concerned with human CD3 binding antibodies comprising a heavy chain and light chain wherein said heavy chain comprises a variable region that comprises the amino acid sequence: QVQLV QSGGG VVQPG RSLRL SCVAS GFTFS SYGMH WVRQA PGKGL EWVAA IWYX1X2RKQDY ADSVK GRFTI SRDNS KNTLY LQMNS LRAED TAVYY CTRGT GYNWF DPWGQ GTLVT VSs with 0-5 amino acid insertions, deletions, substitutions, additions or a combination thereof at one or more positions other than the position indicated by X1X2; wherein X1=N and X2=A; X1=N and X2=T; X1=S and X2=G; X1=H and X2=G; X1=D and X2=G; or X1=H and X2=A. The invention is also concerned with bispecific antibodies that have a heavy chain as defined herein above. The invention is also concerned with methods of production of the antibody, cells producing the antibody and with (medical) uses of the antibody.

Abstract: The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.

Abstract: This invention relates to a method of treating cancer by administering a combination therapy comprising a combination of CSF-1R inhibitor, which is ARRY-382 or a pharmaceutically acceptable salt thereof, and a PD-1 binding antagonist, to a patient in need thereof.

Abstract: The invention relates to a method of removing immune suppression in a tumor microenvironment or stimulating an immune system against cancer cells, comprising administering to a subject a combination of a HDAC inhibitor and an NSAID in combination with an immune checkpoint inhibitor.

Abstract: The present invention provides for an antibody or antigen-binding fragment thereof which binds to an epitope within human PD-L1 with high specificity and reproducibility. The inventive antibody or antigen-binding fragment thereof may be used in assessing PD-L1 expression in tissue samples to aid in patient stratification. The present invention further provides methods of producing the inventive antibody.

Abstract: A method of treating, preventing, or delaying the progression of Type 1 diabetes mellitus autoimmunity by administering an effective amount of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) molecule is provided herewith. The CTLA4 molecule may be a fusion protein of a CTLA4 extracellular region and an immunoglobulin, such as abatacept.

Abstract: The present invention features a novel EGFR variant, EGFRvVI, and methods for detecting the novel EGFR variant. The novel EGFR variant is preferentially expressed in some cancers. Methods for detecting EGFRvVI may aid in the diagnosis, prognosis, and therapeutic assessment of a subject.

Abstract: The invention relates generally to the treatment of cancer. One embodiment of the invention provides a method of treating cancer in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).

Abstract: The present invention provides a cancer microenvironment-targeting anti-podocalyxin antibody or antigen binding fragment thereof.

Abstract: Provided herein are cell populations transiently expressing a chimeric antigen receptor (CAR) and their use in the chronic treatment of hyperproliferative diseases such as cancer.

Abstract: The present invention relates to a pharmaceutical combination which comprises (a) a phosphatidylinositol 3-kinase inhibitor or pharmaceutically acceptable salt thereof, and (b) a Her3 antagonist, for simultaneous, separate or sequential administration for the treatment of breast cancer brain metastases; a method of treating a subject having a breast cancer brain metastases comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of breast cancer brain metastases; and a commercial package comprising such combination.

Abstract: The present invention relates to a Fab fragment based switchable antibody system for generating site-specific antibody conjugates. Methods are described for the attachment of molecules to specific sites the Fab fragment and for the attachment of the Fab fragment to a target molecule (e.g., an antibody) directed against any desired target antigen (tumor, bacterial, fungal, viral, parasitic etc.) The attachment is via binding of the Fab fragment to an epitope linked to the target molecule.

Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.

Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) four moities capable of specific binding to a costimulatory TNF receptor family member, (b) at least one moiety capable of specific binding to a target cell antigen, and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.

Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.

Abstract: The present invention provides methods for producing Fabs and bi-specific antibodies comprising designed residues in the interfaces of the heavy chain-light chain variable (VH/VL) domain and the heavy chain-light chain constant (CH/CL) domain, Fabs and bi-specific antibodies produced according to said processes and host cells encoding the same.

Abstract: Disclosed are a Z-N catalyst for ?-olefin polymerization and an application thereof, specifically, an industrial production catalyst consisting of (A) a solid catalyst component, (B) a cocatalyst organoaluminum compound and (C) an external electron donor compound and used for ?-olefin polymerization or copolymerization processes. The catalyst component is prepared from a transition metal such as titanium and magnesium and a composite aromatic diacid diester/1,3-diether as an internal electron donor. One or more organoaluminum compounds or a mixture thereof serve as the cocatalyst. One or more structure control agent hydrocarbyl alkoxysilicons are compounded with one or more activity regulator organic acid esters as the external electron donor capable of automatically adjusting the polymerization rate. The Z-N catalyst is used for ?-olefin polymerization/copolymerization, and can automatically adjust the polymerization rate at a higher polymerization temperature so as to maintain stable operation of a reactor.

Abstract: The present invention is directed to solid catalyst particles comprising a Ziegler-Natta catalyst and a polymeric nucleating agent. Further, the present invention is also directed to a process for the preparation of said solid catalyst particles, the use of said solid catalyst particles in a process for the manufacture of a polymer and a polyolefin obtained in the presence of said solid catalyst particles.

Abstract: A phthalate-free procatalyst composition is disclosed for olefin polymerization that exhibits excellent polymerization activity and response to hydrogen, and can produce a polyolefin exhibiting high stereoregularity, high melt flow rate, and desirable molecular weight distribution. The method for producing the procatalyst composition includes reaction of a magnesium support precursor with a tetravalent titanium halide and a combination of different internal electron donors. The first internal electron donor may comprise one or more substituted phenylene aromatic diester and the second internal electron donor may comprise a polyether, preferably a 1,3-diether. In one embodiment, the support precursor comprises a spherical spray crystalized MgCl2-EtOH adduct.

Abstract: Disclosed is a catalyst component for olefin polymerization. The catalyst component comprises magnesium, titanium, halogen and an internal electron donor. The internal electron donor includes an imine compound with a ketone group as shown in Formula I. Disclosed further is a method of preparing the catalyst component, and a catalyst for olefin polymerization containing the catalyst component. When the catalyst is used in olefin polymerization reaction especially propene polymerization reaction, the catalyst has a high activity and a long term activity and good hydrogen response, and the obtained polymer has characteristics of an adjustable isotactic index and a relatively wide molecular weight distribution.

Abstract: A method of preparing a silane-functionalized polymer, the method comprising: preparing a polymerization system including a cis-1,4-polydiene by introducing a lanthanide-based catalyst and a conjugated diene monomer; and adding a hydrosilane compound to the polymerization system including a cis-1,4-polydiene.

Abstract: The instant invention provides a polyethylene composition and process for polymerizing the same. The polyethylene composition according to the present invention comprises the polymerization reaction of ethylene and optionally one or more ?-olefin comonomers in the presence of a catalyst system, wherein said polyethylene composition comprises at least 2 or more molecular weight distributions, measured via triple detector GPC low angle laser light scattering (GPC-LALLS), described in further details hereinbelow, wherein each molecular weight distribution has a peak, and wherein measured detector response of peak 1 divided by the measured detector response of peak 2 is in the range of from 0.50 to 0.79, for example from 0.55 to 0.77.

Abstract: The present invention relates to an ethylene/alpha-olefin copolymer and, more particularly, to an ethylene/alpha-olefin copolymer that exhibits excellent environmental stress crack resistance by appropriately controlling the ratio of crystal structure domain and amorphous domain, and the like. The ethylene/alpha-olefin copolymer comprises an ethylene repeating unit and an alpha-olefin repeating unit, and has a crystal structure including a crystalline domain containing lamellar crystals and an amorphous domain containing a tie molecule that mediates bonding between the lamellar crystals. The lamellar crystal thickness (dc) of the ethylene/alpha-olefin copolymer as calculated from the result of Small Angle X-ray Scattering (SAXS) analysis is between 12.0 and 16.0 nm, the amorphous domain thickness (da) is between 4.0 and 5.3 nm, and the thickness ratio da/dc is between 0.3 and 0.4.

Abstract: A polymer compound comprising a repeating unit having at least one group selected from the group consisting of a blocked isocyanato group and a blocked isothiocyanato group, a repeating unit having at least one group selected from the group consisting of a hydroxy group and a carboxy group and a repeating unit represented by the following formula (1), wherein the content of the repeating unit having at least one group selected from the group consisting of a blocked isocyanato group and a blocked isothiocyanato group in the polymer compound is 1% by mol or more and 30% by mol or less when the total content of all repeating units contained in the above-described polymer compound is taken as 100% by mol: in the formula (1), R2, R2 and R3 each independently represent a hydrogen atom or a methyl group.

Abstract: The present invention relates to novel PMMA foams and the production thereof. Here, polymers which have been obtained by copolymerization of methacrylamides such as N-isopropylmethacrylamide and without styrene are foamed. It has surprisingly been possible to establish that a stable, simple-to-produce PMMA foam which has very good properties, e.g. a very high compressive strength, and can be joined more simply to covering layers, especially in comparison with known PMMA foams, can be obtained according to the invention.

Abstract: The invention relates to a copolymer obtained by polymerisation reaction of at least three comonomers: a first anionic monomer, a second monomer comprising an olefin unsaturation, and a third monomer comprising a hydrophobic group. The invention likewise relates to the use of said copolymer as a thickening agent, in particular in aqueous suspensions of mineral particles with high solids content. The copolymer according to the invention makes it possible to improve the compromise between viscosity with high shear gradient and viscosity with low shear gradient, while also improving water retention inside the suspension.

Abstract: The invention relates to a method for producing a polymer from a first component and a second component by means of a reactor (50), wherein reaction heat in the reactor (50) is discharged via an evaporative cooler (40), wherein gaseous exhaust vapour in the reactor (50) is supplied to the evaporative cooler (40), and condensed exhaust vapour is guided from the evaporative cooler (40) back into the reactor (50). In this way, the first component and/or second component are supplied at least partially via the evaporative cooler (40) and moved from the evaporative cooler (40) into the reactor (50). The invention also relates to a system for producing a polymer, comprising a reactor (50) and an evaporative cooler (40) for discharging reaction heat in the reactor (50). In addition, the evaporative cooler (40) has at least one filling opening (46) for filling in the first and/or second component.

Abstract: The present invention relates to coated polymer particles comprising a water-swellable polymer core and an essentially continuous coating encapsulating the core. The coating comprises an oxide, hydroxide or oxide hydrate of silicon, aluminum, zirconium, tin or titanium. The polymer particles do not show instantaneous swelling, when contacted with water or a water-containing liquid, but show delayed water absorption after an appropriate period of time. The coated polymer particles may be used in oil fields, in mining, for construction chemical compositions or as carrier for active substances. The coated polymer particles are prepared by a suspension coating process or a fluidized bed coating process.

Abstract: The invention relates to graft copolymers—based on non-cross-linked acrylate soft phases from which styrenic monomers are grafted—with a defined micro-structure, having a high transparency, toughness and weather resistance (UV-stability), a process for their preparation and their use, and also to polymer blends comprising said graft copolymers and styrenic polymers, and shaped articles produced therefrom and their use.

Abstract: The present invention pertains to a fluorinated thermoplastic elastomer, to a process for the manufacture of said fluorinated thermoplastic elastomer and to uses of said fluorinated thermoplastic elastomer in various applications, especially in low temperature applications.

Abstract: It is an object of the present invention to provide a self-assembly composition for pattern formation having a wide range of applicable pattern size and being capable of forming a favorable phase-separated structure.

Abstract: In one or more embodiments, the present invention provides a novel approach to the addition of plasticizers for softening TPUs, i.e., lowering the durometer and the melt viscosity. This approach involves incorporating bonded sulfonate groups with quaternary ammonium counterions into the TPU. In one or more embodiments of the present invention, the softening of TPU is achieved by incorporating an ionic diol, such as N,N-bis (2-hydroxyethyl)-2-aminoethane-sulfonic acid (BES), coupled with various bulky alkyl ammonium cations, during the chain extension step of the TPU synthesis. It is believed that that steric hindrance of the bulky quaternary ammonium groups weakens the dipole-dipole interactions of the sulfonate groups and/or lowers the crystallinity of the hard block, thereby creating additional free volume that softens the polymer and lowers the melt viscosity.

Abstract: A manner for improving storage stability of a curable resin composition and close adhesion of a cured product to a polycarbonate. The present description relates to a curable resin composition including the following components (A) to (C): component (A): an isocyanate group-containing urethane prepolymer, component (B): a powder of a polyamine compound which is solid at 25° C., and component (C): at least one selected from the group consisting of a monofunctional (meth)acrylate compound having an alicyclic structure or a monofunctional (meth)acrylate compound having an aromatic ring, a monofunctional (meth)acrylate compound having a hydrolyzable silyl group, and a polyfunctional (meth)acrylate compound, where the composition does not substantially include a photoradical initiator.

Abstract: A method for producing a coagulate includes: incorporating, into an aqueous urethane resin composition containing an aqueous urethane resin having an acid value of 0.01 mg KOH/g or more, a thickening agent having an oxyethylene group content of 2×10?2 mol/g or less in an amount in the range of from 0.01 to 30 parts by mass, relative to 100 parts by mass of the aqueous urethane resin, to thicken the composition; and then coagulating the thickened composition using a coagulant containing a metal salt). A porous structure can be formed from an aqueous urethane resin composition without subjecting the composition to heating or foaming step, and therefore a coagulate having a porous structure can be stably obtained with ease.

Abstract: A thermoplastic thiourethane polymer comprising a sequential chain of a first type of monomer covalently bonded to a second type of monomer via thiourethane linkages. The first type of monomer includes two or more thiol functional groups and the type of monomer includes two or more isocyanate functional groups. The first and second types of monomers are polymerized together in an anhydrous aprotic solvent-dissolved anionic step-growth polymerization reaction that is catalyzed by a non-nucleophillic base having a pKa greater than 7.

Abstract: A photoresponsive polyurethane including a hard segment, a soft segment, and a photoresponsive group that is selected from a coumarin group or a coumarin derivative and an alkoxyphencyl group or an alkoxyphencyl.

Abstract: A foaming thermoplastic polyurethane resin is a reaction product of a polyisocyanate component containing a bis(isocyanatomethyl)cyclohexane and a polyol component. In a peak of chromatogram obtained by measurement of the foaming thermoplastic polyurethane resin with gel permeation chromatography, the area of a high molecular weight component having a weight average molecular weight of 400,000 or more with respect to the total area of the peak is 25% or more and 60% or less.

Abstract: Polyamide foams which inhibit the spread of fires for filling cavities in mining Polyamide foams which do not propagate fire are obtained by mixing (i) a liquid isocyanate component which comprises at least one polyisocyanate and in which the molar ratio of aromatic isocyanate groups to the sum of aromatic and aliphatic isocyanate groups is at least 60 mol %, with (ii) at least one liquid isocyanate-reactive component which comprises a reactive diluent, and the reactive diluent comprises (a) a chain-extending and/or crosslinking reactive diluent selected from among aliphatic branched C24-66-polycarboxylic acids, alicyclic C24-66-polycarboxylic acids and partial esters of polycarboxylic acids having at least two unesterified carboxyl groups and/or (b) a chain-terminating reactive diluent selected from among aliphatic branched C24-66-monocarboxylic acids, alicyclic C24-66-monocarboxylic acids and partial esters of polycarboxylic acids having one unesterified carboxyl group, and (iii) optionally a solid isocyana

Abstract: A method for manufacturing a thermally conductive material is provided, which includes mixing 1 part by mole of (a) aromatic epoxy resin monomer, 0.25 to 1 part by mole of (b) cycloaliphatic epoxy resin monomer, and 1 to 9 parts by mole of (c) aliphatic epoxy resin monomer to form a resin composition. The method also includes heating and curing the resin composition to form a thermally conductive material.

Abstract: In some aspects, the present disclosure provides epoxy resins from an epoxide containing aromatic compound. The epoxy resin may further comprise one or more curing agents which change the properties of the epoxy resin. Also described herein are methods of preparing epoxy resins using the epoxide containing aromatic compounds and materials prepared with them.

Abstract: The invention relates to heat-curing and light-fixable epoxy-based compositions which are liquid at room temperature, comprising at least one epoxy-containing compound (A) having at least two epoxy groups, at least one curing agent (B) for the epoxy-containing compound, optionally an accelerator (C), at least one radiation-curing compound (D), at least one photoinitiator (E) for radical polymerization and at least one filler (F). The radiation-curing compound (D) comprises at least one at least trifunctional (meth)acrylate. In particular, the epoxy composition can be used for fixing and/or selectively encapsulating electrical, electronic and/or electromechanical components, and/or for bonding, coating and sealing.

Abstract: A polymer includes: a structural unit represented by the following Formula (I-1) and a structural unit represented by the following Formula (I-2). In Formulae (I-1) and (I-2), X and X? each independently represent a divalent group having 6 to 50 carbon atoms and containing an aromatic ring; Y represents a divalent group having 5 to 50 carbon atoms, the divalent group including an alicyclic ring and alkylene groups, and the alkylene groups each having 1 to 10 carbon atoms connecting carbon atoms included in carbonyl groups adjacent to Y with the alicyclic ring; Y? represents a divalent group having 3 to 50 carbon atoms and containing an alicyclic ring directly bonded to carbon atoms included in carbonyl groups adjacent to Y?; and m and n each represent an integer from 3 to 1,000.

Abstract: In one aspect, oligomeric and polymeric species are described herein exhibiting new architectures and associated properties. In some embodiments, such species are synthesized by oligomerization or polymerization of diene monomer via cycloaddition in the presence of a transition metal complex. Oligomers described herein, for example, comprise cyclobutane units in the oligomer backbone. Similarly, a polymers described herein comprise cyclobutane units in the polymer backbone.

Abstract: The present disclosure is directed to methods of making a polymer, including exposing a reaction mixture including a strained cyclic unsaturated monomer and an organic initiator to a stimulus to provide an activated organic initiator, whereby the activated organic initiator is effective to polymerize the strained cyclic unsaturated monomer via a 4-membered carbocyclic intermediate to provide a polymer having constitutional units derived from the strained cyclic unsaturated monomer.